NASDAQ:COLL - Collegium Pharmaceutical Stock Price, News & Analysis

$12.13
-0.31 (-2.49 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$12.05
Now: $12.13
$12.76
50-Day Range
$10.39
MA: $11.32
$12.81
52-Week Range
$10.01
Now: $12.13
$19.83
Volume303,797 shs
Average Volume360,341 shs
Market Capitalization$406.00 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$280.41 million
Cash Flow$2.1935 per share
Book Value$2.75 per share

Profitability

Net Income$-39,130,000.00

Miscellaneous

Employees266
Market Cap$406.00 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.


Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The specialty pharmaceutical company had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The business's revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) EPS. View Collegium Pharmaceutical's Earnings History.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

What price target have analysts set for COLL?

5 analysts have issued 12-month price targets for Collegium Pharmaceutical's shares. Their predictions range from $22.00 to $33.00. On average, they expect Collegium Pharmaceutical's share price to reach $26.20 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

What is the consensus analysts' recommendation for Collegium Pharmaceutical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Has Collegium Pharmaceutical been receiving favorable news coverage?

Headlines about COLL stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), NVIDIA (NVDA), Celgene (CELG), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (12.95%), Janus Henderson Group PLC (12.95%), BlackRock Inc. (7.43%), Vanguard Group Inc. (4.70%), Rice Hall James & Associates LLC (3.78%) and Morgan Stanley (1.53%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

Which institutional investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, D. E. Shaw & Co. Inc., A.R.T. Advisors LLC, Morgan Stanley, State Board of Administration of Florida Retirement System, Trexquant Investment LP, Bogle Investment Management L P DE and United Services Automobile Association. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

Which institutional investors are buying Collegium Pharmaceutical stock?

COLL stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Cortina Asset Management LLC, Nuveen Asset Management LLC, BlackRock Inc., Eversept Partners LP and Bank of Montreal Can. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $12.13.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $406.00 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.


MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  559
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: CD Ladder

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel